S 120083

Drug Profile

S 120083

Alternative Names: S-120083; V 120083

Latest Information Update: 17 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Purdue Pharma; Shionogi
  • Class Analgesics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Inflammatory pain

Most Recent Events

  • 01 Mar 2017 Phase-II clinical trials in Inflammatory pain in USA (PO) (NCT03028870)
  • 19 Jan 2017 Purdue Pharma in collaboration with Shionogi plans a phase II trial for Pain (NCT03028870)
  • 29 Feb 2016 Phase-I clinical trials in Inflammatory pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top